Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer

Breast Cancer Research and Treatment

Volumn 82, Issue 2, 2003, Pages 113-123

  Assersohn, L ^a   Salter, J ^b   Powles, T J ^a   A'hern, R ^b   Makris, A ^c   Gregory, R K ^d   Chang, J ^e   Dowsett, M ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Ki67; Marker; Predictive; Response

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; MITOXANTRONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; REPRODUCIBILITY; STATISTICAL ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BIOPSY, FINE-NEEDLE; BREAST; BREAST NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; TAMOXIFEN;

EID: 0345688803     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000003968.45511.3f     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942, 1998
2. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E, Wickerham D, Begovic M, DeCillis A, Robidoux A, Margolese R, Cruz AJ, Hoehn J, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998
3. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10: 47-52, 1999
4. Makris A, Powles T, Ashley S, Chang J, Hickish T, Tidy V, Nash A, Ford H: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9: 1179-1184, 1998
5. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999
6. Henderson IC, Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 52: 261-288, 1998
7. Pierga JY, Leroyer A, Viehl P, Mosseri V, Chevillard S, Magdelenat H: Long term prognostic value of growth fraction determination by Ki67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37: 57-64, 1996
8. Railo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K, Nordling S: Ki67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol 36: 369-374, 1997
9. Lee AK, Loda M, Mackarem G, Bosari S, DeLellis RA, Heatley GJ, Hughes K: Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome. Cancer 79: 761-771, 1997
10. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E: Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67: 606-611, 1993
11. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizi MP, DiMarco B, Cirillo F, Bertoli G, Alquati P, Dogliotti L: Relationship between estrogen receptor status and antiproliferative effect of neoadjuvant chemotherapy in primary breast cancer. Proc Annu Meet Am Soc Clin Oncol 15: 1996 (Meeting abstract)
12. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM: Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74: 1458-1465, 1996
13. Honkoop AH, Van Diest PJ, De Jong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J, Pinedo HM: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77: 621-626, 1998
14. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirillo F, Bolsi G, Bertoli G, Alquati P, Dogliotti L: Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16: 3105-3110, 1996
15. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48: 107-116, 1998
16. Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M: Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 48: 11-20, 1998
17. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3: 593-600, 1997
18. Dardes R, Horiguchi J, Jordan V: A pilot study of the effects of short-term tamoxifen therapy on Ki67 labelling index in women with primary breast cancer. Int J Oncol 16: 2000
19. Chang J, Powles T, Allred D, Ashley S, Clark G, Makris A, Assersohn L, Gregory R, Osborne C, Dowsett M: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058-3063, 1999
20. Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M: Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat 53: 51-59, 1999
21. Chang J, Powles T, Allred D, Ashley S, Makris A, Gregory R, Osborne C, Dowsett M: Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 6: 616-621, 2000
22. Hayward J, Carbone P, Heuson J, Kumaoka S, Segaloff A, Rubens R: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292-298, 1977
23. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien MER, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, MacVicar D, Fernando I, Ford HT: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547-552, 1995
24. Iqbal S, Anderson TJ, Marson LP, Prescott RJ, Dixon JM, Miller WR: MIB-1 assessments in breast cancers. The Breast 11: 252-256, 2002
25. Iqbal S, Anderson TJ, Marson LP, Prescott RJ, Dixon JM, Miller WR: MIB-1 assessments in breast cancers. The Breast 11: 252-256, 2002
26. Nizzoli R, Bozzetti C, Naldi N, Guazzi A, Babrielli M, Michiara M, Camisa R, Barilli A, Cocconi G: Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas. Cancer (Cancer Cytopathology) 90: 61-66, 2000
27. Kenny F, Willsher P, Gee J, Nicholson R, Pinder S, Ellis I, Robertson J: Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Res Treat 65: 135-144, 2001
28. Dowsett M, Bundred N, Decensi A, Sainsbury R, Lu Y, Hills M, Cohen F, Veronesi P, O'Brien M, Scott T, Muchmore D: Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiology, Biomarkers Prevent 10: 961-966, 2001
29. Altman DG, Lyman GH: Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289-303, 1998
30. Shipp M, Ross K, Tamayo P, Weng A, Kutok J, Aguiar R, Gaasenbeek M, Angelo M, Reich M, Pinkus G, Ray T, Koval M, Last K, Norton A, Lister T, Mesirov J, Neuberg D, Lander E, Aster J, Golub T: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med 8: 68-74, 2002
31. Rosenwald A, Wright G, Chan W, Connors JE, Fisher R, Gascoyne R, Muller-Hermelink H, Smeland E, Staudt L: The use of molecular profiling to predict survival after chemotherapy for diffuse large B cell lymphoma. N Engl J Med 346: 1937-1947, 2002
32. Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C, Pollack J, Ross D, Johnsen H, Akslen L, Fluge O, Pergamenschikov A, Williams C, Zhu S, Lonning P, Borresen-Dale A, Brown P, Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000
33. Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A, Boldrick J, Sabet H, Tran T, Yu X, Powell J, Yang L, Marti G, Moore T, Hudson J, Lu L, Lewis D, Tabshirani R, Sherlock G, Chan W, Greiner T, Weisenburger D, Armitae J, Warnke R, Levy R, Wilson W, Grever M, Byrd J, Botstein D, Brown P, Staudt L: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000